WASHINGTON, June 11 (Reuters) - The U.S. Senate health

panel said on Tuesday it would vote later this month on whether

to subpoena Novo Nordisk over the high U.S. prices

for weight loss drugs Ozempic and Wegovy compared to those

offered in other countries.

The Senate Committee on Health, Education, Labor, and

Pensions, which is investigating the drugs' costs, will weigh a

subpoena for senior Novo Nordisk Inc executive Doug Langa when

it meets on June 18, it said in a statement.